Perry A. Karsen's most recent trade in Graphite Bio Inc was a trade of 20,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 19, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Graphite Bio Inc | Perry A. Karsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Perry A. Karsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Perry A. Karsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 74,794 | 74,794 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Perry A. Karsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 19,763 | 19,763 | - | - | Series B Preferred Stock | |
| Graphite Bio Inc | Perry A. Karsen | Director | 13 Jan 2021 | 19,763 | 0 | - | - | Series B Preferred Stock | ||
| Graphite Bio Inc | Perry A. Karsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 18,698 | 18,698 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Perry A. Karsen | Director | 13 Jan 2021 | 8,126 | 164,034 | - | - | Common Stock | ||
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Sale of securities on an exchange or to another person at price $ 53.69 per share. | 17 Dec 2020 | 45,450 | 26,336 (0%) | 0% | 53.7 | 2,440,211 | Common Stock |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 17 Dec 2020 | 31,764 | 36,764 (0%) | 0% | 18 | 571,752 | Common Stock |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 31,764 | 0 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Sale of securities on an exchange or to another person at price $ 52.52 per share. | 17 Dec 2020 | 21,978 | 71,786 (0%) | 0% | 52.5 | 1,154,285 | Common Stock |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Sale of securities on an exchange or to another person at price $ 54.33 per share. | 17 Dec 2020 | 21,336 | 5,000 (0%) | 0% | 54.3 | 1,159,185 | Common Stock |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 19,000 | 0 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 19,000 | 0 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 19,000 | 0 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 17 Dec 2020 | 19,000 | 93,764 (0%) | 0% | 15.8 | 299,820 | Common Stock |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.98 per share. | 17 Dec 2020 | 19,000 | 74,764 (0%) | 0% | 26.0 | 493,620 | Common Stock |
| Intellia Therapeutics Inc | Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.35 per share. | 17 Dec 2020 | 19,000 | 55,764 (0%) | 0% | 14.4 | 272,650 | Common Stock |